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Abstract
The ZFP36/Tis11 family of zinc-finger proteins regulate cellular processes by binding to adenine uridine rich elements in the
39 untranslated regions of various mRNAs and promoting their degradation. We show here that ZFP36L1 expression is
largely extinguished during the transition from B cells to plasma cells, in a reciprocal pattern to that of ZFP36 and the
plasma cell transcription factor, BLIMP1. Enforced expression of ZFP36L1 in the mouse BCL1 cell line blocked cytokine-
induced differentiation while shRNA-mediated knock-down enhanced differentiation. Reconstruction of regulatory
networks from microarray gene expression data using the ARACNe algorithm identified candidate mRNA targets for
ZFP36L1 including BLIMP1. Genes that displayed down-regulation in plasma cells were significantly over-represented
(P =,0.0001) in a set of previously validated ZFP36 targets suggesting that ZFP36L1 and ZFP36 target distinct sets of
mRNAs during plasmacytoid differentiation. ShRNA-mediated knock-down of ZFP36L1 in BCL1 cells led to an increase in
levels of BLIMP1 mRNA and protein, but not for mRNAs of other transcription factors that regulate plasmacytoid
differentiation (xbp1, irf4, bcl6). Finally, ZFP36L1 significantly reduced the activity of a BLIMP1 39 untranslated region-driven
luciferase reporter. Taken together, these findings suggest that ZFP36L1 negatively regulates plasmacytoid differentiation,
at least in part, by targeting the expression of BLIMP1.
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Introduction
The ZFP36/Tis11 zinc finger protein family bind to adenine
uridine (AU)-rich elements (AREs) in the 39 untranslated regions
of mRNAs and mediate ARE-mediated mRNA decay [1]. There
are four mammalian members of the ZFP36 family that include
the prototype, ZFP36 (Tis11, TTP, Nup475, GOS24), ZFP36L1
(Tis11b, BERG36, ERF-1, BRF-1) and ZFP36L2 (Tis11d, ERF-2,
BRF-2). The fourth family member described in rodents,
ZFP36L3, is expressed in mouse placenta, but apparently not in
human placenta or other human tissues [2].
Binding of ZFP36/Tis11 proteins to AREs of their target
mRNAs promotes deadenylation, decapping and finally, degra-
dation by either exosome (39-59 degradation) or XRN1
exonuclease (59-39 degradation) [3–5]. In addition, some
ZFP36/Tis11 family members attenuate translation of their
target mRNAs by inhibiting recruitment to polyribosomes [6].
The post-transcriptional regulatory functions of ZFP36/Tis11
proteins have also been reported to overlap and interact with
those of microRNAs [7]. Sets of mRNA targets for individual
ZFP36/Tis11 family members have been identified in several
studies [8,9] are reviewed in [4,5] and include a number of key
cytokines such as IL-2 [10], IL-3 [11,12], IL-10 [9]. An
emerging picture is that each ZFP36/Tis11 protein targets a
distinct, but overlapping repertoire of probably several hundred
mRNAs. Cell-type-specificity is further imparted by the distinct
expression pattern of each family member.
We originally identified the human ZFP36L1 gene (10A/
Berg36) from a panel of cDNAs representing early response
genes from activated B lymphocytes [13,14]. ZFP36L1 is
essential for embryonic development [6,15] and in common
with other ZFP36/Tis11 family members, possesses proapopto-
tic functions [14,16,17]. In B cells, expression of ZFP36L1 is
inducible by a diverse range of activating signals [13,14,17,18],
suggesting that it may serve additional biological roles in this
cell lineage. Prompted by recent data showing that ZFP36L1
serves an essential role in maintaining the undifferentiated state
of myeloid [19] and pluripotent embryonic stem cells [20], we
have investigated a possible role for this protein in B cell
plasmacytoid differentiation using the mouse BCL1 cell line.
These cells can be induced to undergo plasmacytoid differen-
tiation in response to cytokines (IL-2/IL-5) and are a useful
in vitro model system to study plasma cell differentiation [21].
We report here that ZFP36L1 negatively regulates plasmacytoid
differentiation, at least in part by targeting mRNA for the
plasma cell regulatory transcription factor, BLIMP1.
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Materials and Methods
Cell Culture
BCL1 mouse B cell leukemia cells were obtained from the
European collection of cell cultures (ref. No. 90061904) and
maintained in RPMI 1640, 10% FBS, 50 U/ml penicillin/
streptomycin, 2 mM LGlutamine,1% sodium pyruvate, 1% non-
essential amino acids, and 0.05 mM 2-mercaptoethonal. Ramos
cells (European collection of cell cultures ref. No. 85030802), and
SEM [22], Nalm6 [23], JJN3 [24], KMM1 [25], MM1S (ATCC,
CRL-2974), RPMI-8226 (ATCC, CCL-155) and KMS-11 [26]
cells (all obtained from Prof. K Yong, Dept. of Haematology,
University College London, UK) were maintained in RPMI 1640,
10% FBS, 50 U/ml penicillin/streptomycin and 2 mM L-
Glutamine. B Cells were isolated from spleens of C57BL/6 mice
using DynalR Mouse B-Cell Negative Isolation Kit (Invitrogen,
Paisley, UK). Primary splenic murine B Cells were maintained in
RPMI 1640, 10% FBS, 50 U/ml penicillin/streptomycin and
0.05 mM b-mercaptoethanol. BCL1 cells seeded at 26105 cells/
ml were stimulated with 20 ng/ml recombinant mouse Interleu-
kin-2 (R&D Systems, Abingdon, UK) and 5 ng/ml recombinant
mouse Interleukin-5 (R&D Systems). Primary murine splenic B
cells seeded at 16106 cells/ml were stimulated with 10 mg/ml
lipopolysaccharide (Sigma-Aldrich, Poole, UK).
Over-expression of ZFP36L1 in BCL1 cells
A cDNA encoding the ZFP36L1 open reading frame was
cloned into the pcDNA3 plasmid (pcDNA3ZFP36L1) and this or
empty pcDNA3 was co-transfected with pcDNA3EGFP plasmid
into BCL1 cells by electroporation. After 24h, transfected cells
were sorted on the basis of EGFP expression using a flow Dako
Cytomation Mo-Flo Fluorescence Activated Cell Sorter. Sorted
BCL1 transfected cells were cultured in medium alone or with IL-
2 and IL-5 for up to four days.
Modulation of ZFP36L1 Levels using a shRNA Expressing
Lentivirus in BCL1 cells
zfp36l1-shRNA lentiviruses were constructed by cloning zfp36l1
shRNAs (Table S1) into the pSicoR lentiviral vector [27]. 10 mg
lentiviral plasmid DNA pSicoR and 5 mg each of the packaging
plasmid DNA (pMDLg/pRRE, pRSV-Rev and pMD2.G) were
added to HEK 293T cells for production of virus as described
previously [27]. Stable mammalian BCL1 cell lines containing the
zfp36l1-shRNAs, empty lentivirus or a scrambled version of the
zfp36l1-shRNA were prepared following transduction of cells with
virus and cell sorting GFP positive cells on a flow cytometer.
Efficiency of ZFP36L1 knockdown was assessed by qRT-PCR and
Western Blot analysis.
Western Blot Analysis
Western Blot analysis was carried out as previously described
[14]. Protein extracts were separated by SDS-PAGE Electropho-
resis and electrotransferred onto nitrocellulose membranes (Pro-
tranR, Schleicher and Schuell, Dassel, Germany) which were
blocked overnight at 4uC in blocking buffer containing 5% milk
powder and TTBS buffer (23 mM Tris base, 0.5 M NaCl, and
0.05% Tween-20). Nitrocellulose membranes were incubated with
appropriate dilution of the following primary antibodies for 1h;
rabbit polyclonal anti-BRF1/2 (ZFP36L1/2) (Cell Signalling,
Danvers, MA, USA), goat anti-ZFP36 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-BLIMP1 (Cell Signalling).
Rabbit anti-HSP90 (Santa Cruz Biotechnology) and rabbit anti-
human bACTIN antibodies (Cell Signalling) were used as loading
control antibodies. Following this incubation, membranes were
washed and incubated with horseradish peroxidise-conjugated
swine anti-rabbit or donkey anti-goat immunoglobulin for 1 h.
Chemiluminescent signals on membranes were detected using
SuperSignalR West Femto Substrate (Pierce, Rockford, IL,USA)
and exposed to X-Ray films (Kodak Biomax MS, Sigma). The
films were developed in a Xograph Compact x4 film processor
(Xograph Imaging Systems Ltd. Tetbury, UK).
Enzyme Linked Immunosorbent Assay (ELISA) for
Measurement of Secreted IgM
ELISA was performed in 96-well Maxisorb Immunoplates
(Nunc. Ltd, Bedford, UK). The plates were coated with rat anti-
mouse IgM antibody (BD Biosciences) and kept overnight at 4uC
in a damp box. Wells were then washed three times with PBS/
0.1% Tween20, and were then blocked with PBS/1% BSA for 1 h
at 37uC. After washing the plates four times with PBS/0.1%
Tween20 different concentration of mouse IgM (Sigma-Aldrich) or
cell supernatant samples were added to wells and the plates
incubated at 37uC for 1 h. Plates were then washed four times
with PBS/0.01% Tween20 and 100 ml of goat anti-mouse IgM
Peroxidase Conjugate antibody (Sigma-Aldrich) was added to each
well. The plates were then incubated at 37uC for 1 h and 30 min.
Plates were washed five times with PBS/0.1% Tween20, and 50 ml
of 3,39,5,59 Tetramethylbenzidine (TMB) was added to each well.
The reaction was terminated with 50 ml/well of 2 M sulphuric
acid and the optical densities read at 450 nm using a Multiscan
plate reader. Concentrations of IgM in cell supernatants were
calculated by reference to the standard curve.
RT-PCR Analysis
Total RNA was extracted from cells using an RNeasy Mini Kit
(Qiagen, Crawley, UK). 1 mg of total RNA was reverse-
transcribed for cDNA synthesis using a QuantiTect Reverse
Transcription kit (Qiagen). PCR was carried out in a Biometra
UNO II thermocycler (Biometra, Gottingen, Germany) in a total
volume of 20 ml containing; 2 ml Reaction buffer (l00 mM Tris-
HCl, 500 mM KCL, 15 mM MgCl2, 1% Triton X-100), 800 mM
PCR nucleotide mix (final concentration of 200 mM of each
dNTP), 0.5 mM of each primer, 50–200 ng of template DNA,
2.5 U Taq DNA polymerase, and nuclease-free water. The
thermal cycling profile was 1 cycle of 95uC for 2 min, followed
by 30 cycles of 94uC for 30 sec, 56uC for 30 sec, and 72uC for
1 min. The primers used were; human ZFP36L1 primers, forward
59- GATGACCACCACCCTCGT-39 and reverse 59
CTGGGAGCACTATAGTTGAGCA-39, human BLIMP1 prim-
ers, forward 59-ACGTGTGGGTACGACCTTG-39 and reverse
59-CTGCCAATCCCTGAAACCT-39 human b ACTIN primers,
forward 59-CCAACCGCGAGAAGATGA-39 and reverse 59-
CCAGAGGCGTACAGGGATAG-39.
Real-time RT-PCR Analysis
Wild-type, control empty lentivirus, scramble lentivirus and
zfp36l1 shRNA knockdown BCL1 were treated with and without
cytokines for various time periods. 1 mg of total RNA was reverse
transcribed for cDNA synthesis using a QuantiTect Reverse
Transcription kit (Qiagen). Real-time quantitative RT-PCR (qRT-
PCR) was performed using an ABI PrismR 7000 Sequence
Detection System (Applied Biosystems, Carlsbad, CA, USA), in a
total volume of 25 ml containing 500 ng of cDNA, 26 Quanti-
TectR SYBRR Green Master mix (Qiagen), and 0.5–1 mM of
each primer. All PCR reactions were carried out in triplicate. The
PCR program consisted of 1 initial cycle of 15 min at 95uC, 40
cycles of 15 sec at 95uC, 15 sec at 60uC, and 30 sec at 72uC. The
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Figure 1. ZFP36L1 expression in human B cells at various stages of differentiation. (A) RT-PCR analysis of ZFP36L1 expression in human
malignant B cells representing different stages of B cell differentiation. For comparison BLIMP1 expression was also measured. b ACTIN expression
levels are shown as a loading control. (B) Comparison of ZFP36L1 protein levels in human Ramos B cells before and after 3 h PMA stimulation and in
two myeloma cell lines RPMI-8226 cells and KMS-11. BLIMP1 expression is also shown in RPMI-8226 cells and KMS-11 cells. HSP90 levels are shown as
a loading control. ZFP36L1/L2, HSP90 and BLIMP1 proteins were detected by anti-BRF1/2, anti-HSP90 and anti-BLIMP1 antibodies respectively. Anti-
BRF1/2 antibody cross-reacts with ZFP36L2 (approx. 60 kDa) and ZFP36L1 appears typically as a constellation of induced bands (approx. 40 kDa) in
human cells.
doi:10.1371/journal.pone.0052187.g001
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Figure 2. Significant downregulation of ZFP36L1 is associated with plasmacytoid differentiation of B cells. (A) Western Blot analysis of
ZFP36L1 expression in IL-2/5 treated murine leukemic BCL1 cells. Protein lysates were made from unstimulated cells (lane 1) or from cells 96 h after
stimulation with cytokines (20 ng/ml IL-2 and 5 ng/ml IL-5) (lane 2). ZFP36L1 and HSP90 proteins were detected by anti-BRF1/2 and anti-HSP 90
antibodies respectively. (B) qRT-PCR analysis of zfp36l1 and blimp1 mRNA expression in day 0 versus 48 h IL-2/5 stimulated BCL1 cells. (C) qRT-PCR
analysis of time course of zfp36l1 and blimp1 mRNA expression over 3 days in LPS (10 mg/ml) stimulated murine splenic B cells. The 2–DDCT method of
relative quantification was used to determine the fold change in mRNA expression. The results shown were normalized to b-actin mRNA expression.
The results show mean 6SD from one representative experiment.
doi:10.1371/journal.pone.0052187.g002
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relative changes in gene expression levels were calculated using the
2–DDCT method [28]. The primer pairs used for qRT-PCR were as
follows; mouse zfp36l1 forward 59-TTCACGACACACCA-
GATCCT-39 and reverse 59-TGAGCATCTTGT-
TACCCTTGC-39, mouse blimp1 59-GGCTCCACTACCCT-
TATCCTG-39 and reverse 59-
GTTGCTTTCCGTTTGTGTGA-39, mouse xbp1 forward 59-
TGACGAGGTTTCAGAGGTG-39 and reverse 59-TGCA-
GAGGTGCACATAGTCTG-39, mouse irf4 forward 59-ACAG-
CACCTTATGGCTCTCTG-39 and reverse 59-ATGGGGTGG-
CATCATGTAGT-39, bcl6 primers, forward
59CTGCAGATGGAGCATGTTGT 39and reverse
59GCCATTTCTGCTTCACTGG39 and mouse b actin primers,
forward 59-CTAAGGCCAACCGTGAAAAG-39 and reverse 59-
ACCAGAGGCATACAGGGACA-39.
39UTR Luciferase Reporter Assay
The human BLIMP1 39UTR was cloned into the pMIR
luciferase reporter vector to generate pMIRBLIMP1 39UTR
luciferase reporter vector (cat. No. SC18855, OriGene Technol-
ogies Inc, Rockville, USA). 24 h prior to transfection HEK 293T
cells (26105 cells/ml) were seeded per well of a 12 well plate. Cells
were then transfected with 100 ng of pMIRBLIMP1 39UTR
luciferase reporter vector alone or with 200 ng of human
ZFP36L1 expression vector (pcDNA6ZFP36L1) or ZFP36L1 with
a zinc finger domain mutation (pcDNA6ZFP36L1 Mut). A renilla
expression vector (10 ng, pRL-CMV, Promega,) was also included
in all transfections. Cells were left for 24 h after transfection, then
cell lysates were prepared, and luciferase and renilla signals
measured using the Dual luciferase reporter assay syatem
(Promega) on a Fluostar Optima (BMG, Labtech) plate reader.
Reverse Engineering of a ZFP36L1 Gene Regulatory
Network in B cells
A U133A (Affymetrix, Santa Clara, CA, USA) expression
profiling microarray dataset (GSE6691) of 56 samples representing
primary normal and malignant mature B and plasma cells [29]
was used for analysis. Pre-processing by filtering of RMA-
normalised log-transformed data for ‘present’ calls and subsequent
analysis was performed using the GenePattern suite of software
tools [30]. Differentially expressed genes were identified by using
the ComparativeMarkerSelection module [31] using a T-test
statistic with a Bonferroni-corrected P value cut-off of 0.05 or a
false discovery rate (FDR) cut-off of 0.01. The microarray dataset
was digitally deconvoluted using the ARACNe algorithm [32,33]
with a mutual information (MI) threshold of 0.41 and a data
processing inequality (DPI) tolerance of 0.175 together with an
expanded list of 1300 human transcription factors for DPI
correction [34]. The resulting network was visualised and further
analysed using the Cytoscape (version 2.6.0) graph mapping
platform [35]. Enrichment of Gene Ontology terms for ARACNe-
inferred ZFP36L1 targets was determined using the GO-
TermFinder algorithm [36].
Statistical Analysis
A students T test was performed wherever applicable. The p
values are indicated as follows: *p,0.05, **p,0.01, ***p,0.001.
Results
ZFP36L1 Expression During B cell Differentiation
The transcription factor, BLIMP1, drives differentiation of B
cell to plasma cells [37–39]. We therefore initially evaluated
expression of ZFP36L1 in parallel with BLIMP1 at different stages
of B cell differentiation by RT-PCR using human B cell tumour
cell lines representing stages of B cell development from pre-B to
plasma cells. As shown in Fig. 1A, ZFP36L1 mRNA was detected
at high levels in the pre-B cell lines, SEM and NALM 6 in which
expression of BLIMP1 mRNA was absent. RAMOS mature B
cells expressed the highest level of ZFP36L1 with detectable
expression of BLIMP1 mRNA. All three cell lines of myeloma
origin (representing plasma cells) expressed higher levels of
BLIMP1 with either lower (JJN3, KMM1) or absent (MMIS)
expression of ZFP36L1 mRNA. Thus, although the expression
patterns of ZFP36L1 and BLIMP1 were not mutually exclusive,
there appeared to be an overall trend of ZFP36L1 expression that
was reciprocal to that of the plasma cell regulator, BLIMP1 and
that decreased in cell lines of plasma cell phenotype. Analysis of
ZFP36L1 protein also revealed very low/absent levels of ZFP36L1
in myeloma cells compared to unstimulated and PMA-stimulated
Ramos Burkitt lymphoma cells (Fig. 1B). We next evaluated
whether induced plasmacytoid differentiation of the murine BCL1
cell line is accompanied by down-regulation of ZFP36L1. BCL1
cells expressed relatively high levels of zfp36l1 mRNA and protein
that were both down-regulated following IL-2/5 stimulation when
blimp1 mRNA expression was upregulated (Fig. 2A and B). With
regard to the two other members of the ZFP36 family, ZFP36L2
was undetectable in BCL1 cells (Fig. 2A) whereas ZFP36 was
expressed but levels of expression were unaffected by IL-2/5
stimulation (Fig. S1). Stimulation of primary murine B lympho-
cytes with LPS also resulted in a reduction in zfp36l1 mRNA that
was essentially complete by day 1 post-stimulation. Blimp1
expression was up-regulated (2.5-fold) at this time point and
Figure 3. Ectopic expression of ZFP36L1 in BCL1 cells inhibits
cytokine-induced. IgM production. Levels of IgM production in
ZFP36L1 transfected BCL1 stimulated with IL-2/5 (20 ng/ml IL-2 and
5 ng/ml IL-5) over 4 days compared to levels produced by empty vector
BCL1 cells cultured under the same conditions. Cells were co-
transfected with either pcDNA3.ZFP36L1 or empty pcDNA3 vector
and pcDNA3.EGFP and then sorted on the basis of EGFP expression
before been set up in culture in the absence or presence of cytokines.
Cells were cultured at 4.06104/ml and ELISA measurements were made
in duplicate. The results shown are representative of 3 similar
experiments.
doi:10.1371/journal.pone.0052187.g003
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continued to accumulate over the following 2 days (Fig. 2C).
Finally, immunohistochemical analysis revealed high levels of
ZFP36L1 protein expression in human tonsil sections that was
predominantly localised to proliferating B cells in germinal centres
(Fig. S1).
ZFP36L1 Regulates the Differentiation of BCL1 cells
To determine whether down-regulation of ZFP36L1 is required
for B cell differentiation, we evaluated the effect of transfecting
BCL1 cells with the vector, pcDNA3ZFP36L1, encoding exoge-
nous ZFP36L1 in combination with an EGFP expressing vector.
Following culture of EGFP positive cell sorted populations in the
presence of IL-2/5, the extent of IgM production at days 3–4 was
markedly reduced in pcDNA3ZFP36L1-expressing cells compared
with control cells expressing empty vector, pcDNA3 (Fig. 3).
Ectopic expression of ZFP36L1 did not affect cell viability or
proliferation of BCL1 cells under these conditions (data not
shown). The impaired differentiation of pcDNA3ZFP36L1-
expressing cells implies that down-regulation of ZFP36L1 is
normally required for plasmacytoid differentiation; the higher
levels of ZFP36L1 seen in BCL1 cells prior to differentiation
induction implicates ZFP36L1 function in maintaining the
immature differentiation state of BCL1 cells.
To further investigate the role of ZFP36L1 in proliferation and
differentiation of BCL1 cells, lentivirus constructs expressing two
different zfp36l1 shRNAs (pSicoR.zfp36l1.RNAi1 and pSi-
Figure 4. Effective downregulation of zfp36l1 mRNA and protein expression by zfp36l1 shRNA lentivirus (pSicoR.zfp36l1) in
independent lentiviral transduced BCL1 cell lines. (A) qRT-PCR analysis of zfp36l1 mRNA levels in pSicoR.zfp36l1.RNAi1 and
pSicoR.zfp36l1.RNAi2 lentivirus infected cells compared to wild-type, empty vector or pSicoR.scramble.RNAi infected cells. The results represent
mean 6SD (n = 3) of zfp36l1 mRNA levels in three independent cells lines generated by three independent rounds of lentiviral infection for each cell
type (apart from wild-type). * = p,0.05 as determined by t-test. (B) Western blot analysis of ZFP36L1 protein expression in wild-type, empty vector,
scramble, pSicoR.scramble.RNAi1and pSicoR.scramble.RNAi2 cells. HSP90 levels are shown as a loading control.
doi:10.1371/journal.pone.0052187.g004
ZFP36L1 Regulates Differentiation of BCL1 Cells
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e52187
Figure 5. Lentiviral-mediated knockdown of ZFP36L1 expression in BCL1 cells promotes plasmacytoid differentiation by inducing
IgM production. Cell numbers in the absence (A) and presence (B) of cytokines (IL-2 and IL-5) in pSicoR.zfp36l1.RNAi1 and pSicoR.zfp36l1.RNAi2
BCL1 cells compared to compared to wild-type, empty vector or pSicoR.scramble.RNAi infected cells. Cells numbers were counted in quadruplicate
4 days after seeding 26105/ml cells on day 0 in flasks in the absence or presence of cytokines (IL-2 20 ng/ml and IL-5 5 ng/ml). Mean 6SD (n = 3) are
shown for three independent cell lines generated for each of the lentivirus infected cells. IgM secretion (ng/ml) measured by ELISA, 4 days after the
start of the culture, in the absence (C) and presence (D) of cytokines (IL-2 20 ng/ml and IL-5 5 ng/ml) in pSicoR.zfp36l1.RNAi1 and
pSicoR.zfp36l1.RNAi2 BCL1 cells compared to compared to wild-type, empty vector or pSicoR.scramble.RNAi infected cells. Mean 6SD (n = 3) are
shown for three independent cell lines generated for each of the lentivirus infected cells. ** = p,0.01, * = p,0.05 as determined by t-test.
doi:10.1371/journal.pone.0052187.g005
ZFP36L1 Regulates Differentiation of BCL1 Cells
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coR.zfp36l1.RNAi2) were designed to target and knock-down
expression of ZFP36L1. As shown in Fig. 4, transduction with both
pSicoR.zfp36l1.RNAi1 and pSicoR.zfp36l1.RNAi2 was effective
in down-regulating endogenous ZFP36L1 in BCL1 cells at both
protein and mRNA levels (Fig. 4A and B). pSicoR.zfp36l1.RNAi-
transduced BCL1 cells proliferated less than wild-type, scramble or
empty vector pSicoR virus control BCL1 cells in the absence of
cytokines although this effect did not reach statistical significance
(Fig. 5A). Similarly, no significant effect on cell proliferation was
seen following cytokine induction in pSicoR.zfp36l1.RNAi-trans-
duced cells (Fig. 5B). However, knock-down of ZFP36L1 induced
a significant increase in IgM production in the absence of
Figure 6. Microarray expression profile and ARACNe network of ZFP36L1. (A) Heat map expression profile of known ZFP36L1 target genes
in terminal B cell differentiation. The profiles are compared with the reference genes, ZFP36L1, BLIMP1 and XBP1 (first three rows). GMCSF, VEGFA
and IL-3 are validated ZFP36L1 targets; the remaining genes have been validated for ZFP36 [4]. Data was taken from GEO Accession number GSE 6691
[29]. Red indicates high and blue, low expression. Key: CLL: B chronic lymphocytic leukemia, MM: multiple myeloma, WM-BL: Waldenstrom’s
macroglobulinemia B cells, WM-PB: Waldenstrom’s macroglobulinemia plasma cells, NBC: normal B cells, PC: normal plasma cells. (B) Graphical
representation of the ARACNe network for BLIMP1 and ZFP36L1. Nodes representing the BLIMP1 and ZFP36L1 hubs are shown enlarged. Only first
neighbours of these hubs are shown in the module. Nodes representing inferred BLIMP1 targets (significantly up-regulated in normal B cells) are blue;
nodes representing inferred ZFP36L1 targets (significantly up-regulated in normal plasma cells) are red. Network graphics were generated as group
attribute layout using Cytoscape version 2.6.0. [35].
doi:10.1371/journal.pone.0052187.g006
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cytokines (Fig. 5C) and a more modest increase was seen in the
presence of cytokines IL-2/5 which did not reach statistical
significance (Fig. 5D). These observations indicate that loss of
ZFP36L1 expression promotes plasmacytoid differentiation of
BCL1 cells.
Reconstruction of the Gene Regulatory Network of
ZFP36L1 in B cells
To investigate the molecular mechanisms through which the
functions of ZFP36L1 are integrated in the gene regulatory
programme orchestrating B cell differentiation, we performed
data-mining of a large microarray gene expression dataset [29]
representing primary normal and malignant mature B and plasma
cells. As shown in Fig. 6A, the expression profile of ZFP36L1
parallels that seen in the various B cell lines (Fig. 1) with high
expression in cells of B cell phenotype and low expression in
normal/malignant plasma cells. Significantly, the expression
profile of ZFP36L1 was reciprocal to that of the B cell
transcription factors, BLIMP1 and XBP1, that are known to
function as key regulators of plasma cell differentiation [37,38].
Several other genes whose mRNAs are well-characterised targets
of ZFP36 family members were also expressed in a reciprocal
pattern to that of ZFP36L1 (Fig. 6A) suggesting that they may also
Figure 7. qRT-PCR analysis of plasmacytoid differentiation associated mRNAs in different BCL1 cell lines. qRT-PCR analysis of blimp1,
xbp1, irf4 and bcl6 mRNA expression in pSicoR.zfp36l1.RNAi1 and pSicoR.zfp36l1.RNAi2 BCL1 cells compared to compared to wild-type, empty vector
or pSicoR.scramble.RNAi infected cells. Cells were cultured in medium alone for 48h. Total RNA was extracted from 56106 cells, 1 mg RNA was reverse
transcribed and the resulting cDNA was used as template for qRT-PCR assay with mouse gene specific primers for blimp1, xbp1, irf4 and bcl6. The 2–
DDCT method of relative quantification was used to determine the fold change in mRNA expression compared to levels in wild-type cells. Mean 6SD
(n = 3) are shown for three independent cell lines generated for each of the lentivirus infected cells. * = p,0.05 as determined by t-test.
doi:10.1371/journal.pone.0052187.g007
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be targeted by ZFP36L1 in B cells, but not in plasma cells where
ZFP36L1 is down-regulated.
Interestingly, we also observed that the expression pattern of the
ZFP36L1 gene is reciprocal to that of ZFP36 (Fig. 6A) suggesting
that the ZFP36 protein may target a distinct set of mRNAs that
are down-regulated in plasma cells. To explore this, we examined
the expression profile of a 393 gene signature representing
mRNAs that have been identified as direct ZFP36 targets by
immunoprecipitation and Affymetrix GeneChip analysis in
dendritic cells [40]. Fig. S2 shows a heat map expression profile
of these genes in the microarray dataset. At least in normal B
lymphocytes and plasma cells, most of these genes are down-
regulated in plasma cells relative to normal B cells (a reciprocal
expression pattern to that of ZFP36– see Fig. 6). Indeed, genes that
display significant down-regulation in normal plasma relative to
normal B cells were significantly over-represented in the 393 gene
signature (P=,0.0001 by Chi-square test). This was confirmed by
Gene Set Enrichment Analysis (Fig. S3). It therefore seems highly
likely that many of mRNAs encoded by these genes are targeted
by ZFP36 (but not by ZFP36L1) in plasma cells.
To more objectively identify candidate mRNA targets for
ZFP36L1 at a global level in mature B cells and to investigate how
the functions of this protein are integrated in the plasmacytoid
differentiation programme, the ARACNe algorithm (algorithm for
the reconstruction of accurate gene regulatory cellular networks)
[32,33] was used to reconstruct a gene regulatory network using
the microarray dataset used in Fig. 6A [29]. As shown in Fig. 6B,
ZFP36L1 forms part of a module that is intimately associated with
BLIMP1. In addition to being directly connected, the ZFP36L1
and BLIMP1 hubs share numerous first neighbours in the network
(a spring-embedded graphic layout of the network is shown in Fig.
S4). In order to reduce the incidence of ‘false-positives’ of inferred
gene targets, we applied a stringent filter of significant up-
regulation in normal B cells for BLIMP1 and of significant up-
regulation in normal plasma cells for ZFP36L1. This approach
was validated by determining whether the resulting list of 138
inferred BLIMP1 targets (Table S2) was significantly enriched for
known (experimentally validated) targets for this transcription
factor. The BLIMP1-inferred targets accounted for 16 out of a list
of 64 genes (25%) that are negatively regulated by BLIMP1 in
plasma cell differentiation in experimental studies [37,41]. This
figure increases to 25 genes (39%) when all inferred BLIMP1
targets are considered without applying the filter of significant up-
regulation in normal B cells, but only at the expense of a lower
enrichment score (data not shown). Overall, 11.6% of the 138
inferred BLIMP1 targets (Table S2) represent known targets for
this transcription factor. Although relatively modest, this level of
enrichment is highly statistically significant (P =,0.0001 by Chi-
square test). It should also be born in mind that the full set of genes
that is repressed by BLIMP1 in plasma cells is likely to far exceed
the 64 genes that have been experimentally validated in earlier
studies [37,41].
When ZFP36L1-inferred targets were filtered for significant up-
regulation in plasma cells, the resulting list comprised just 23
candidate target mRNAs (Table S3); the top-ranked scores for
enrichment of Gene Ontology terms of this gene list are shown in
Table S4. The proteins encoded by genes such as GAS6 (growth
arrest) and GFI1 (transcriptional repression) –Table S4, would be
expected to perform important roles in the plasma cell differen-
tiation programme. Significantly, the list also included BLIMP1
itself which, together with CD38 and SEL1L encode mRNAs
containing canonical 39 ARE elements that are targeted by the
ZFP36 protein family [4]. The absence of such regulatory
elements in mRNAs of the remaining 20 genes is not unexpected;
previous studies have shown that only a small minority of mRNAs
that are functionally targeted by the related protein, ZFP36,
contain AREs [4,40]. Although none of the previously well-
characterised ZFP36 family targets shown in Fig. 6A were
represented in the ARACNe network shown in Fig. 6B, most of
these genes were found to be directly connected to ZFP36L1 in
ARACNe networks constructed using lower MI and higher DPI
tolerance thresholds, but only by incurring an unacceptable false-
positive rate (data not shown).
Blimp1 mRNA Level is Regulated by ZFP36L1
To experimentally validate mRNA targets for ZFP36L1 that are
functionally important in regulating B cell differentiation, we
focussed on BLIMP1, inferred from ARACNe analysis above,
together with three other key transcriptional regulators of plasma
cell differentiation, XBP1, IRF4 and BCL6 [37–39]. As shown in
Figure 8. ZFP36L1 knockdown in BCL1 cells is associated with
BLIMP1 upregulation and ZFP36L1 interacts with the BLIMP
39UTR. (A) Western blot analysis of BLIMP1 levels in control and
ZFP36L1 knockdown cells. BLIMP1 expression levels are upregulated in
ZFP36L1 knockdown cells compared to controls. bACTIN levels are
shown as a loading control. (B) ZFP36L1 mediates degradation of the
BLIMP1 39UTR. HEK 293 T cells were transfected with pMIRBLIMP1
39UTR construct alone (control) or with either ZFP36L1 or a zinc finger
domain mutant, ZFP36L1 Mut. Renilla luciferase was also included in all
transfections as a normalization control. 24 hours later cell lysates were
harvested and firefly and renilla luciferase levels measured using a
Fluorstar Optima plate reader. Relative levels of luciferase activity were
measured. Mean 6SD, are shown for four independent experiments
(n = 4), * = p,0.05 as determined by t-test.
doi:10.1371/journal.pone.0052187.g008
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Fig. 7, the expression of xbp1, irf4 and bcl6 mRNAs were not
significantly affected in pSicoR.zfp36l1.RNAi transduced BCL1
cells compared to control cells in the absence of cytokine
induction. By contrast, there was a significant increase in levels
of blimp1 mRNA seen before cytokine treatment in pSi-
coR.zfp36l1.RNAi1-transduced BCL1 cells compared to controls,
with a smaller increase in pSicoR.zfp36l1.RNAi2-transduced
BCL1 cells (Fig. 7). There was also a trend towards higher blimp1
mRNA levels that did not reach statistical significance in the
presence of cytokines (data not shown). Importantly, pSi-
coR.zfp36l1.RNAi-transduced BCL1 cells expressed higher levels
of BLIMP1 protein compared to control cells (Fig. 8A). Finally, a
functional effect of ZFP36L1 on the BLIMP1 39UTR sequence
was demonstrable by luciferase reporter assay in which wild-type
ZFP36L1 significantly reduced BLIMP1 39UTR-driven luciferase
levels compared to a zinc finger mutant version of ZFP36L1
(Fig. 8B).
Discussion
Accumulating evidence implicates the mRNA destabilisation
protein, ZFP36L1, in the regulation of self-renewal and differen-
tiation in cells of diverse lineages including haematopoietic cells
[5]. In mouse embryonic stem (ES) cells, high levels of ZFP36L1
reportedly maintain an undifferentiated state with down-regula-
tion inducing differentiation to cardiomyocytes [20]. Similarly, in
CD34+ hematopoietic stem cells, ZFP36L1 negatively regulates
erythroid differentiation [42]. ZFP36L1 has also been found to be
overexpressed in cell lines and primary cells expressing the AML1-
ETO fusion protein that is found in 40% of Acute Myeloid
Leukaemia of M2 sub-type. Enforced over-expression of ZFP36L1
promotes proliferation and inhibits differentiation of these cells
[19]. Finally, in mouse thymocytes, targeted deletion of the
ZFP36L1 and ZFP36L2 genes leads to a perturbation of NOTCH-
1-regulated thymic development in vivo with accumulation of T
cell antigen receptor b-chain-negative cells culminating in T
lymphoblastic leukaemia [43].
The results from our study implicate ZFP36L1 in playing a key
role in B lymphopoiesis by regulating the transition from mature B
cell to plasma cell. In cell line models and murine primary B cells,
ZFP36L1 expression was high in B lymphocytes, but largely
extinguished in plasma cells. Enforced expression of ZFP36L1 in
the mouse BCL1 cell line blocked cytokine-induced differentiation
while shRNA-mediated knock-down of this gene enhanced
cytokine-induced differentiation. These observations are consistent
with ZFP36L1 being required to negatively regulate terminal
plasmacytoid differentiation.
By using an information-theoretic method for reconstruction of
gene regulatory networks (ARACNe) [32,33], we inferred a direct
regulatory interaction between ZFP36L1 and the plasma cell
transcription factor, BLIMP1. shRNA-mediated knock-down of
ZFP36L1 in BCL1 cells led to a modest, but significant increase in
blimp1 mRNA and protein levels. The mRNA expression levels of
other key transcriptional regulators of plasmacytoid differentiation
(xbp1, irf4, bcl6) [38,39] was unaffected by ZFP36L1 knock-down.
In further experiments, we have similarly observed no effect of
ZFP36L1 knock-down on mRNA levels of pax5 (data not shown).
Since BLIMP1 mRNA harbours a canonical AU-rich recognition
motif in its 39UTR, we hypothesised that it was highly likely that
ZFP36L1 directly regulates BLIMP1 expression by targeting its
mRNA and we found evidence for this in BLIMP 39 UTR
luciferase reporter assays. The elevated levels of blimp1 mRNA
and protein seen in ZFP36L1-knock-down BCL1 cells could at
least in part explain the enhanced differentiation seen in these cells
as evidenced by increased IgM secretion. Interestingly, ZFP36L1
has previously been identified as part of a signature of genes that is
repressed by BLIMP1 in B cells during the transition of mature B
cells to plasma cells [37,41]. More recently, ZFP36L1 has been
identified as a direct BLIMP1 target gene in B-lineage cells by
chromatin immunoprecipitation analysis [44]. Thus, ZFP36L1
and BLIMP1 may exist in a regulatory feedback loop where
ZFP36L1 suppresses premature/leaky BLIMP1 expression in B
cells; in response to triggers of differentiation, accumulating levels
of BLIMP1 would then transcriptionally silence ZFP36L1
expression, allowing plasma cell differentiation to proceed.
ARACNe analysis also identified a number of other candidate
mRNA targets of ZFP36L1. Whether these are targeted via their
39 UTRs and their roles in regulating plasmacytoid differentiation
remains to be determined. However, several well-characterised/
validated targets of ZFP36 family members were identified that
displayed a reciprocal pattern of expression to ZFP36L1. Most
notable amongst these were four genes for which there is direct
experimental evidence for their roles in regulating B cell
differentiation, Fos [45], GMCSF, IL3 [46] and COX2 [47]. In
further experiments, we observed no effect of anti-GMCSF
antibody on IL-2/IL-5-induced differentiation of BCL1 cells (J
Murphy, unpublished observations). However, given that
ZFP36L1 likely targets mRNAs of multiple genes that act
cooperatively to orchestrate the transition from B-cells to plasma
cells, the value of such ‘single candidate gene’ experiments is
questionable. Finally, we noted a reciprocal pattern of expression
between ZFP36L1 and ZFP36 in cells of B lymphocyte and plasma
cell phenotype. Moreover, genes that displayed significant down-
regulation in normal plasma cells relative to normal B cells were
significantly over-represented in ZFP36 targets that have previ-
ously been validated in dendritic cells [40]. Given the mutually
exclusive expression patterns of their genes, it follows that the
ZFP36L1 and ZFP36 proteins would target distinct sets of mRNAs
during the transition of B-cell to plasma cells.
Supporting Information
Figure S1 ZFP36L1 and ZFP36 expression in B cells. Immu-
nohistological staining of tonsil germinal centres with (A) anti-
ZFP36L1 antibody, (B) with control rabbit serum. Sections are
shown (40X magnification) after counterstaining with haemotox-
ylin. Arrows depict the mantle zone region surrounding a germinal
centre. (C) Western blot showing ZFP36 expression in IL-2/5
treated murine leukemic BCL1 cells. Protein lysates were made
from cells 96 h after stimulation with cytokines (20 ng/ml IL-2
and 5 ng/ml IL-5) (lane 1) or from unstimulated cells (lane 2).
ZFP36 and HSP90 proteins were detected by anti-ZFP36 and
anti-HSP90 antibodies respectively.
(TIF)
Figure S2 Heat map expression profile of ZFP36 dendritic cell
target genes in terminal B cell differentiation. The profiles of 393
mRNAs that have been identified as ZFP36 targets by immuno-
precipitation and Affymetrix GeneChip analysis in dendritic cells
[40] is shown. The majority of these mRNAs that are expressed in
normal B lymphocytes are down-regulated in normal plasma cells,
consistent with them being targets for ZFP36. Data was taken from
GEO Accession number GSE 6691 [29]. Red indicates high and
blue, low expression. Key: CLL: B chronic lymphocytic leukemia,
MM: multiple myeloma, WM-BL: Waldenstrom’s macroglobuli-
nemia B cells, WM-PB: Waldenstrom’s macroglobulinemia
plasma cells, NBC: normal B cells, PC: normal plasma cells.
(TIF)
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Figure S3 Genes that are down-regulated in normal plasma cells
vs B cells are enriched in a set of validated ZFP36 target genes.
Gene set enrichment analysis (GSEA) [48] according to up-
regulation (signal-to-noise test statistic) in normal B cells relative to
plasma cells is shown as a profile of running Kolmogorov-Smirnov
ES score and positions of ZFP36 marker genes (black bars) in the
rank ordered list of differentially expressed genes. The normalised
enrichment score was 1.72 (P=,0.00001) corrected for 1000 gene
permutation tests. Of the 371 unique ZFP36 target genes [40],
annotated in GSEA, 200 are represented in the leading edge.
(TIF)
Figure S4 Graphical representation of the ARACNe network
for BLIMP1 and ZFP36L1. Nodes representing the BLIMP1 and
ZFP36L1 hubs are shown enlarged. Only first neighbours of these
hubs are shown in the module. Nodes representing inferred
BLIMP1 targets (significantly up-regulated in normal B cells) are
blue; nodes representing inferred ZFP36L1 targets (significantly
up-regulated in normal plasma cells) are red. Network graphics
(spring-embedded layout) were generated using Cytoscape version
2.6.0.
(TIF)
Table S1 Oligonucleotide primers designed for construction of
zfp36l1 shRNA and scramble sequences.
(DOC)
Table S2 BLIMP1 target genes inferred from ARACNe
analysis. The Bonferroni-corrected P values (P =#0.05) for the
significance of up-regulation in normal B cells are shown. Known
BLIMP targets were taken from the SignatureDB [37,41].
(DOC)
Table S3 ZFP36L1 targets inferred from ARACNe analysis.
Values of the false discovery rate (FDR=#0.01) for enrichment in
normal plasma cells are shown. Data on the presence and type of
ARE element were taken from the ARED database [49].
(DOC)
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